Form 4: Moderna's Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.
Summary
- Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., filed a Form 4 detailing changes in beneficial ownership of company stock.
- On August 30, 2024, 233 shares were acquired through the conversion of restricted stock units (RSUs).
- On September 3, 2024, 114 shares were disposed of at a price of $76.989 per share to cover tax withholding obligations related to the vesting of RSUs.
- Following these transactions, Klinger directly owns 17,566 shares of Moderna common stock and 1,396 restricted stock units.
- The sales were mandated by Moderna's equity incentive plans to cover tax obligations and do not represent discretionary trades.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions by an officer. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- It's standard practice for executives at publicly traded companies, such as Pfizer, BioNTech, and Johnson & Johnson, to file Form 4s when they trade their company's stock.
- The 'sell to cover' mechanism for tax obligations is a common feature in equity compensation plans across the pharmaceutical and biotechnology industries.
- The vesting schedule of the restricted stock units (25% initially, then quarterly) is a typical vesting arrangement seen in many companies' equity plans.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- The filing provides transparency to shareholders regarding insider trading activities.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | 25% of the shares subject to the restricted stock unit award vested |
| 08/30/2024 | 233 shares acquired through conversion of Restricted Stock Units |
| 09/03/2024 | 114 shares disposed of at $76.989 to cover tax obligations |
| 09/04/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.